Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 2/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 7/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675783 | 0.85 | MAP2K4 (0.49) | MAP2K4PRKCIFYNFGFR1CDK8 | |
| SCHEMBL16675766 | 0.85 | PRKCI (0.46) | MAP2K4PRKCIFYNFGFR1CDK8 | |
| SCHEMBL16675782 | 0.85 | MAP2K4 (0.55) | MAP2K4PRKCIFYNFGFR1CDK8 | |
| SCHEMBL931989 | 0.77 | PRKCI (0.51) | MAP2K4PRKCIFYNFGFR1CDK8 | |
| SCHEMBL16675768 | 0.74 | FYN (0.55) | PRKCIFYNCDK8CYP2C9NR4A2 | |
| SCHEMBL10725996 | 0.72 | JAK3 (0.51) | — | |
| SCHEMBL12523764 | 0.71 | PRKCI (0.56) | MAP2K4PRKCIFYNCDK8CYP2C9 | |
| SCHEMBL12986756 | 0.71 | MAPK1 (0.42) | MAP2K4FGFR1 | |
| SCHEMBL16675785 | 0.70 | PRKCI (0.64) | MAP2K4PRKCIFYNFGFR1CDK8 | |
| SCHEMBL31500185 | 0.70 | PRKCI (0.50) | PRKCIFYNCDK8SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855489-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | MAP2K4 2548/4885PRKCI 3236/4885FYN 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.